ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio LEIDEN, Netherlands & CAMBRIDGE, Mass., … a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in June 2021 with the …
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases
… ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 LEIDEN, … include, but are not limited to, statements regarding our Axiomer® technology and our participation at this conference. …
… ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform … transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted …
… ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event Initial … during which the Company will showcase its proprietary Axiomer RNA-editing technology platform, detail the pipeline, …
